NCT06694363View on ClinicalTrials.gov

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase Δ Syndrome

Not yet recruitingOBSERVATIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

May 31, 2029

Conditions
Activated PI3K Delta Syndrome
Interventions
BIOLOGICAL

Blood samples

A maximum of 27 ml of blood collected at each visit for metabolic markers analysis

BIOLOGICAL

Urine samples

One urine sample collected at each visit for enteric virus infection research

BIOLOGICAL

Stool samples

One stool sample collected at each visit for enteric virus infection research

Trial Locations (7)

13000

Hôpital La Timone adulte - MARSEILLE, Marseille

33000

Hôpital Haut Levêque - BORDEAUX, Bordeaux

Hôpital Pellerin Enfants - BORDEAUX, Bordeaux

59000

Hôpital Jeanne de Flandres - LILLE, Lille

75015

Hôpital Necker Enfants Malades - PARIS, Paris

Unknown

CHU IUCT Oncopole - TOULOUSE, Toulouse

Hôpital des enfants - TOULOUSE, Toulouse

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06694363 - New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase Δ Syndrome | Biotech Hunter | Biotech Hunter